2013 White Paper on recent issues in bioanalysis: 'Hybrid' - The best of LBA and LCMS

Bioanalysis

Volumn 5, Issue 23, 2013, Pages 2903-2918

  Stevenson, Lauren ^a   Garofolo, Fabio ^b   Desilva, Binodh ^c   Dumont, Isabelle ^b   Martinez, Suzanne ^b   Rocci, Mario ^d   Amaravadi, Lakshmi ^a   Brudny Kloeppel, Margarete ^e   Musuku, Adrien ^f   Booth, Brian ^g   Dicaire, Catherine ^b   Wright, Laura ^h   Mayrand Provencher, Laurence ^b   Losauro, Mike ^h   Gouty, Dominique ^h   Arnold, Mark ^c   Bansal, Surendra ⁱ   Dudal, Sherri ^j   Dufield, Dawn ^k   Duggan, Jeff ^l   Evans, Christopher ^m   Fluhler, Eric ^k   Fraser, Stephanie ^k   Gorovits, Boris ^k   Haidar, Sam ^g   Hayes, Roger ⁿ   Ho, Stacy ^o   Houghton, Richard ^p   Islam, Rafiqul ^q   Jenkins, Rand ^r   Katori, Noriko ^s   Kaur, Surinder ^t   Kelley, Marian ^u   Knutsson, Magnus ^v   Lee, Jean ^w   Liu, Hanlan ^o   Lowes, Steve ^x   Ma, Mark ^w   Mikulskis, Alvydas ^a   Myler, Heather ^c   Nicholson, Bob ^r   Olah, Timothy ^c   Ormsby, Eric ^y   Patel, Shefali ^z   Pucci, Vincenzo ^aa   Ray, Chad ^k   Schultz, Gary ^x   Shih, Judy ^w   Shoup, Ronald ^ab   Simon, Craig ^y   Song, An ^t   Neto, João Tavares ^ac   Theobald, Valerie ^ad   Thway, Theingi ^w   Wakelin Smith, Jason ^ae   Wang, Jian ^c   Wang, Laixin ^af   Welink, Jan ^ag   Whale, Emma ^ae   Woolf, Eric ^aa   Xu, Raymond ^ah   more..

^a BIOGEN   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d ICON Development Solutions   (United States)

^e BAYER PHARMA AG   (Germany)

^f Pharmascience   (Canada)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h Intertek   (United States)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k PFIZER INC   (United States)

^l BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^m GLAXOSMITHKLINE   (United States)

ⁿ MPI RESEARCH   (United States)

^o Sanofi   (United States)

^p Quotient Bioresearch Ltd   (United Kingdom)

^q CELERION   (United States)

^r Pharmaceutical Product Development   (United States)

^s NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^t GENENTECH INC   (United States)

^u MKelley Consulting LLC   (United States)

^v Ferring Pharmaceuticals AS   (Denmark)

^w AMGEN INC   (United States)

^x IQVIA   (United States)

^y HEALTH CANADA   (Canada)

^z Janssen RandD   (United States)

^aa MERCK RESEARCH LABORATORIES   (United States)

^ab AIT Bioscience   (United States)

^ac Agencia Nacional de Vigilancia Sanitaria Brazil   (Brazil)

^ad SANOFI   (France)

^ae MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^af Northwest Toxicology Inc   (United States)

^ag MEDICINES EVALUATION BOARD   (Netherlands)

^ah ABBVIE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; GLASS; NEUTRALIZING ANTIBODY; POLYPROPYLENE; POLYSTYRENE;

8 HYPERLIPIDEMIC MATRIX TEST; ANTIDRUG ANTIBODY TEST; ANTIGEN BINDING; ARTICLE; BLOOD; BLOOD STABILITY; CEREBROSPINAL FLUID; FIT FOR PURPOSE; HUMAN; HYBRID; HYDROPHOBICITY; IMMUNOASSAY; IMMUNOGENICITY; INCURED SAMPLE STABILITY; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS SPECTROMETRY; METABOLITE; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR STABILITY; NONHUMAN; PARALLELISM; PHYSICAL CHEMISTRY; PLASMA; PROTEIN PROCESSING; RECEPTOR BINDING ASSAY; SENSITIVITY AND SPECIFICITY; TRACHEOBRONCHIAL TOILET; VALIDATION PROCESS;

ANIMALS; BIOCHEMISTRY; BIOMARKERS, PHARMACOLOGICAL; CALIFORNIA; CHEMISTRY TECHNIQUES, ANALYTICAL; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; PHARMACOKINETICS; VALIDATION STUDIES AS TOPIC;

EID: 84890390856     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.238     Document Type: Article

References (28)

1. Savoie N, Booth BP, Bradley T et al. 2008 White Paper: The 2nd calibration and validation group workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis 1(1), 19-30 (2009
2. Savoie N, Garofolo F, van Amsterdam P et al. 2009 White Paper on recent issues in regulated bioanalysis from the 3rd calibration and validation group workshop. Bioanalysis 2(1), 53-68 (2010
3. Savoie N, Garofolo F, van Amsterdam P et al. 2010 White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis 2(12), 1945-1960 (2010
4. Garofolo F, Rocci M, Dumont I et al. 2011 White Paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis 3(18), 2081-2096 (2011
5. DeSilva B, Garofolo F, Rocci M et al. 2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis 4(18), 2213-2226 (2012
6. Lowes S, Jersey J, Shoup R et al. Recommendations on: Internal standard criteria; stability; ISR and recent 483s by the Global CRO Council (GCC) for Bioanalysis. Bioanalysis 3(12), 1323-1332 (2011
7. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006
8. Breda M. Garofolo F, Caturla MC et al. The 3rd Global CRO Council (GCC) for bioanalyis at the international reid bioanalytical forum. Bioanalysis 3(24), 2721-2727 (2011
9. Hougton R, Gouty D, Allinson J et al. Recommendations on biomarker bioanalytical method validation by GCC. Bioanalysis 4(20), 2439-2446 (2012
10. O'mara M, Hudson-Curtis B, Olson K et al. The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis 3(20), 2335-2347 (2011
11. Jonsson O, Villar RP, Nilsonn LB et al. Capillary microsampling of 25 μl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis 4(6), 661-674 (2012
12. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valprolic acid serum level by assay of a single pooled sample. Clin. Pharmacol. Ther. 29(3), 408-413 (1981
13. Ji AJ, Jiang Z, Livson Y, Davis JA et al. Challenges in urine bioanalytical assays: Overcoming nonspecific binding. Bioanalysis 2(9), 1573-1586 (2010
14. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LCMS/MS. Bioanalysis 3(12), 1379-1397 (2011
15. ANVISA. Manual for Good Bioavailability and Bioequivalence Practices. Brazilian Sanitary Surveillance Agency, Brazil (2003
16. EMA, Committee for Medicinal Products for Human Use. Draft Guideline on Validation of Bioanalytical Methods. London, UK (2009
17. EMA, Committee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. London, UK (2011
18. ANVISA. Resolution RDC no. 27, May 17, 2012. Brazilian Health Surveillance Agency, Brazil (2012
19. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20, 1885-1900 (2003
20. Rodbard D, Feldman Y, Jaffe ML et al. Kinetics of two-site immunoradiometric (sandwich) assays-II. Immunochem. 15, 77-82 (1978
21. Kelley M, Ahene AB, Gorovits B et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 15(3), 646-658 (2013
22. Lee J, Kelley M, King L et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: Technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011
23. Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J. Pharm. Biomed. Anal. 55, 878-888 (2011
24. Kaur S, Xu K, Saad OM et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013
25. Gorovits B, Alley SC, Bilic S et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9) 997-1006 (2013
26. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research. Guidance for Industry, Investigators, and Reviewers. Exploratory IND Studies. FDA, Rockville, MD, USA (2006
27. Ramagiri S, Garofolo F. Large molecule bioanalysis using Q-TOF without predigestion and its data processing challenges. Bioanalysis 4(5), 529-540 (2012
28. Morin LP, Mess JN, Garofolo F. Large-molecule quantification: Sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. Bioanalysis 5(10), 1181-1193 (2013